CHA Vaccine Research Institute (KOSDAQ:261780)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,985.00
+125.00 (3.24%)
At close: Apr 28, 2026
33.50%
Market Cap 104.64B
Revenue (ttm) 158.62M
Net Income (ttm) -16.04B
Shares Out 26.87M
EPS (ttm) -597.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 959,288
Average Volume 1,604,114
Open 3,940.00
Previous Close 3,860.00
Day's Range 3,735.00 - 4,080.00
52-Week Range 2,280.00 - 6,720.00
Beta 0.07
RSI 56.30
Earnings Date n/a

About KOSDAQ:261780

Cha Vaccine Research Institute Co., Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products for infectious and chronic diseases. Its product pipeline includes HBV vaccine that is in Phase IIb planning for the prevention of hepatitis B; Adjuvanted HBV vaccine that is in Phase I/IIa for the treatment of chronic hepatitis B; and VZV Vaccine, which is in pre-clinical planning stage for the prevention of Herpes Zoster. The company also develops influenza vaccine, recombinant MBL, TB vaccine, and cancer va... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 261780
Full Company Profile

Financial Performance

In 2025, KOSDAQ:261780's revenue was 158.62 million, a decrease of -57.21% compared to the previous year's 370.66 million. Losses were -16.04 billion, 58.3% more than in 2024.

Financial Statements

News

There is no news available yet.